Market Research Logo

Uveitis - Pipeline Review, H2 2015

Uveitis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Uveitis - Pipeline Review, H2 2015’, provides an overview of the Uveitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Uveitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Uveitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Uveitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Uveitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Uveitis Overview
Therapeutics Development
Pipeline Products for Uveitis - Overview
Pipeline Products for Uveitis - Comparative Analysis
Uveitis - Therapeutics under Development by Companies
Uveitis - Therapeutics under Investigation by Universities/Institutes
Uveitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Uveitis - Products under Development by Companies
Uveitis - Products under Investigation by Universities/Institutes
Uveitis - Companies Involved in Therapeutics Development
2-BBB Medicines BV
AbbVie Inc.
Aciont Inc.
Aldeyra Therapeutics, Inc.
Apitope International NV
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd.
Clearside BioMedical, Inc.
Effimune SAS
Endocyte, Inc.
Enzo Biochem, Inc.
EyeGate Pharmaceuticals, Inc.
HanAll Biopharma Co., Ltd.
Icon Bioscience, Inc.
IMMD Inc.
Innomedica Ltd.
Johnson & Johnson
Kineta, Inc.
Neuroptis Biotech
Novartis AG
Ocata Therapeutics, Inc.
OncoNOx ApS
Palatin Technologies, Inc.
Panoptes Pharma Ges.m.b.H.
Pfizer Inc.
pSivida Corp.
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
SynDevRx, Inc.
ThromboGenics NV
TxCell SA
Virogenomics, Inc.
XOMA Corporation
Uveitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
2B3-201 - Drug Profile
abatacept - Drug Profile
adalimumab - Drug Profile
ATXUV-1 - Drug Profile
ATXUV-2 - Drug Profile
B27-PD - Drug Profile
celecoxib - Drug Profile
Col-Treg - Drug Profile
cyclosporine SR - Drug Profile
Cytectin - Drug Profile
dalazatide - Drug Profile
dexamethasone acetate - Drug Profile
dexamethasone acetate - Drug Profile
dexamethasone sodium phosphate - Drug Profile
Drug for Chronic Uveitis - Drug Profile
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile
EC-1496 - Drug Profile
EC-1669 - Drug Profile
fluocinolone acetonide SR - Drug Profile
FR-104 - Drug Profile
gevokizumab - Drug Profile
HL-036 - Drug Profile
IMD-0354 - Drug Profile
INV-17 - Drug Profile
LFG-316 - Drug Profile
LME-636 - Drug Profile
lodamin - Drug Profile
methotrexate - Drug Profile
NOP-3 - Drug Profile
NS-2 - Drug Profile
Oligonucleotides to Activate IL-10 for Uveitis - Drug Profile
OX-1001 - Drug Profile
PA-2612 - Drug Profile
Peptides to Modulate TCR for Uveitis - Drug Profile
piclidenoson - Drug Profile
PL-8177 - Drug Profile
plastoquinone decyl triphenylphosphonium bromide - Drug Profile
PP-001 - Drug Profile
PPL-003 - Drug Profile
Recombinant Enzymes for Uveitis - Drug Profile
sarilumab - Drug Profile
sirolimus - Drug Profile
Small Molecules to Inhibit 5-lipoxygenase for Uveitis - Drug Profile
Stem Cell Therapy for Autoimmune Diseases - Drug Profile
TG-931 - Drug Profile
TOP-1288 - Drug Profile
triamcinolone acetonide - Drug Profile
triamcinolone acetonide - Drug Profile
Uveitis - Recent Pipeline Updates
Uveitis - Dormant Projects
Uveitis - Discontinued Products
Uveitis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Uveitis, H2 2015
Number of Products under Development for Uveitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Uveitis - Pipeline by 2-BBB Medicines BV, H2 2015
Uveitis - Pipeline by AbbVie Inc., H2 2015
Uveitis - Pipeline by Aciont Inc., H2 2015
Uveitis - Pipeline by Aldeyra Therapeutics, Inc., H2 2015
Uveitis - Pipeline by Apitope International NV, H2 2015
Uveitis - Pipeline by Bristol-Myers Squibb Company, H2 2015
Uveitis - Pipeline by Can-Fite BioPharma Ltd., H2 2015
Uveitis - Pipeline by Clearside BioMedical, Inc., H2 2015
Uveitis - Pipeline by Effimune SAS, H2 2015
Uveitis - Pipeline by Endocyte, Inc., H2 2015
Uveitis - Pipeline by Enzo Biochem, Inc., H2 2015
Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2015
Uveitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Uveitis - Pipeline by Icon Bioscience, Inc., H2 2015
Uveitis - Pipeline by IMMD Inc., H2 2015
Uveitis - Pipeline by Innomedica Ltd., H2 2015
Uveitis - Pipeline by Johnson & Johnson, H2 2015
Uveitis - Pipeline by Kineta, Inc., H2 2015
Uveitis - Pipeline by Neuroptis Biotech, H2 2015
Uveitis - Pipeline by Novartis AG, H2 2015
Uveitis - Pipeline by Ocata Therapeutics, Inc., H2 2015
Uveitis - Pipeline by OncoNOx ApS, H2 2015
Uveitis - Pipeline by Palatin Technologies, Inc., H2 2015
Uveitis - Pipeline by Panoptes Pharma Ges.m.b.H., H2 2015
Uveitis - Pipeline by Pfizer Inc., H2 2015
Uveitis - Pipeline by pSivida Corp., H2 2015
Uveitis - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Uveitis - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2015
Uveitis - Pipeline by SynDevRx, Inc., H2 2015
Uveitis - Pipeline by ThromboGenics NV, H2 2015
Uveitis - Pipeline by TxCell SA, H2 2015
Uveitis - Pipeline by Virogenomics, Inc., H2 2015
Uveitis - Pipeline by XOMA Corporation, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Uveitis Therapeutics - Recent Pipeline Updates, H2 2015
Uveitis - Dormant Projects, H2 2015
Uveitis - Dormant Projects (Contd..1), H2 2015
Uveitis - Dormant Projects (Contd..2), H2 2015
Uveitis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Uveitis, H2 2015
Number of Products under Development for Uveitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report